Grundinformationen
- Standard-SMILES
O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+]- InChIKey
KPHWPUGNDIVLNH-UHFFFAOYSA-M- Summenformel
- C14H10Cl2NNaO2
- Durchschnittliche Molmasse
- 318,1 g/mol
- Monoisotopische Masse
- 316,9986282
Überblick
Diclofenac sodium is the sodium salt of diclofenac. It contains a diclofenac(1-).
Namen und Bezeichner
- Bevorzugter Name
- Diclofenac sodium
- IUPAC
- sodium 2-[2-(2,6-dichloroanilino)phenyl]acetate
Namen und Synonyme
Diclofenac sodium15307-79-6Diclofenac sodium saltSodium diclofenacSolarazeNeriodinProphenatinVoltarenDiclophenac sodiumAbitrenBenfofenDyloject
Weitere Namen anzeigen
EcofenacPennsaidVoltareneVoltaren-XRGP 45840DiclophlogontDealgicDeflamat
Datenbank-Bezeichner
- CAS
15307-79-6- PubChem CID
- 5018304
- DTXSID
DTXSID3037208- ChEMBL
CHEMBL1034- ChEBI
CHEBI:4509- UNII
- QTG126297Q
- EC Number
- 239-346-4
- Nikkaji
- J8.556A
Eigenschaften
Berechnete Struktureigenschaften
- Polarare Oberfläche (TPSA)
- 52,2 Ų
- H-Brücken-Donoren
- 1
- H-Brücken-Akzeptoren
- 3
- Frei drehbare Bindungen
- 4
- Schwere Atome
- 20
- Formalladung
- 0
- Komplexität
- 310
Experimentelle und physikochemische Eigenschaften
Human Drugs
Breast Feeding; Lactation; Milk, Human; Analgesic Agents; Anti-inflammatory Agents, Nonsteroidal
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Animal DrugsActive Ingredients (Diclofenac sodium) -> FDA Greenbook
Collision Cross Section157.2 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
Sicherheit und Regulatorisches
GHS-Klassifizierung
GHS Classification
Danger
H301 (96.7%): Toxic if swallowed [Danger Acute toxicity, oral]
P203, P260, P261, P264, P264+P265, P270, P271, P273, P280, P301+P316, P302+P352, P304+P340, P305+P351+P338, P316, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 243 reports by companies from 43 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Gefahrenhinweise
Regulatory Information
Status: Active Update: 27-05-2019 https://echa.europa.eu/registration-dossier/-/registered-dossier/13423
Diclofenac sodium: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, monosodium salt: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 3 (96.7%)
Toxikologische Informationen
Exposure RoutesCompletely absorbed from the gastrointestinal tract.
Toxicity Summary
The antiinflammatory effects of diclofenac are believed to be due to inhibition of both leukocyte migration and the enzyme cylooxygenase (COX-1 and COX-2), leading to the peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, inhibition of their synthesis is responsible for the analgesic effects of diclofenac. Antipyretic effects may be due to action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat dissipation.
Signs and SymptomsSymptoms of overdose include loss of consciousness, increased intracranial pressure, and aspiration pneumonitis.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Diclofenac sodium
vMost-DILI-concern
8
Warnings & precautions
DOI:10.1016/j.drudis.2016.02.015
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD<sub>50</sub>=390mg/kg (orally in mice)
Chemie und Industrie
Pharmakologische Informationen
Metabolism/Metabolites
Hepatic. Route of Elimination: Diclofenac is eliminated through metabolism and subsequent urinary and biliary excretion of the glucuronide and the sulfate conjugates of the metabolites. Little or no free unchanged diclofenac is excreted in the urine. Approximately 65% of the dose is excreted in the urine and approximately 35% in the bile as conjugates of unchanged diclofenac plus metabolites. Half Life: 2 hours
FDA Pharmacological Classification
DICLOFENAC SODIUM
Cyclooxygenase Inhibitors [MoA]; Nonsteroidal Anti-inflammatory Drug [EPC]; Anti-Inflammatory Agents, Non-Steroidal [CS]; Decreased Prostaglandin Production [PE]
DICLOFENAC SODIUM 1%
Cyclooxygenase Inhibitors [MoA]; Anti-Inflammatory Agents, Non-Steroidal [CS]; Decreased Prostaglandin Production [PE]; Nonsteroidal Anti-inflammatory Drug [EPC]
DICLOFENAC SODIUM D/R
Cyclooxygenase Inhibitors [MoA]; Nonsteroidal Anti-inflammatory Drug [EPC]; Decreased Prostaglandin Production [PE]; Anti-Inflammatory Agents, Non-Steroidal [CS]
MeSH Pharmacological Classification
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.
Verwendung und Herstellung
UsesFor the acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis.
Use ClassificationAnimal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients
Zugehörige Reaktionen
24
Verknüpfte Notizen
Wird geladen…